Literature DB >> 7685176

Prevalence of ectopic ventricular activity after left ventricular mass regression.

R A González-Fernández1, M Rivera, P J Rodríguez, J Fernández-Martínez, L H Soltero, L M Díaz, J E Lugo.   

Abstract

To assess the effects of left ventricular mass reduction on the prevalence of ventricular ectopic activity, we conducted a double-blind, placebo-controlled trial measuring ambulatory 48 h premature ventricular depolarizations in 27 patients with mild-to-moderate hypertension and an increased left ventricular mass index. Data was obtained at baseline and 6 +/- 2 months after randomization to either 25 mg captopril or placebo twice a day. Patients on captopril attained reduction in blood pressure from 167 +/- 11/103 +/- 6 to 136 +/- 10/85 +/- 5 mm Hg (P = .001), left ventricular mass index regression from 149 +/- 17 to 96 +/- 23 g/m2 (P = .001), and ventricular ectopic activity reduction from 413 +/- 172 to 77 +/- 27 ventricular extrasystoles/day (P = .001). Patients on placebo had no significant change in blood pressure (from 162 +/- 11/101 +/- 6 at baseline to 160 +/- 8/100 +/- 8 mm Hg after 6 months; P = NS). In the placebo group left ventricular mass index increased from 155 +/- 40 to 182 +/- 51 g/m2 (P = .01), and ventricular ectopic activity decreased from 634 +/- 293 to 562 +/- 260 ventricular extrasystoles/day (P = NS). Eight out of 14 patients on captopril (57%) and 1 out of 13 patients on placebo (8%) achieved reduction > 85% in ventricular ectopic activity per day (P = .004). Using multivariate logistic regression analysis, left ventricular mass index regression and reduction in systolic blood pressure were the most important correlates for this effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685176     DOI: 10.1093/ajh/6.4.308

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

Review 1.  Management of premature ventricular complexes.

Authors:  Albert K Chan; Mary L Dohrmann
Journal:  Mo Med       Date:  2010 Jan-Feb

2.  Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia.

Authors:  Cordula M Wolf; Ivan P G Moskowitz; Scott Arno; Dorothy M Branco; Christopher Semsarian; Scott A Bernstein; Michael Peterson; Michael Maida; Gregory E Morley; Glenn Fishman; Charles I Berul; Christine E Seidman; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-06       Impact factor: 11.205

Review 3.  Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death.

Authors:  F H Messerli; F Soria
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

Review 4.  Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Authors:  W Linz; G Wiemer; J Schaper; R Zimmermann; K Nagasawa; P Gohlke; T Unger; B A Schölkens
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

Review 5.  Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?

Authors:  Wadih Nadour; Robert W W Biederman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-08       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.